CA2232876A1 - Proteine de fusion du ligand fas - Google Patents

Proteine de fusion du ligand fas Download PDF

Info

Publication number
CA2232876A1
CA2232876A1 CA002232876A CA2232876A CA2232876A1 CA 2232876 A1 CA2232876 A1 CA 2232876A1 CA 002232876 A CA002232876 A CA 002232876A CA 2232876 A CA2232876 A CA 2232876A CA 2232876 A1 CA2232876 A1 CA 2232876A1
Authority
CA
Canada
Prior art keywords
protein
hfasl
gly
glycophospholipid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002232876A
Other languages
English (en)
Inventor
Thomas Buehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2232876A1 publication Critical patent/CA2232876A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette protéine comprend, d'une part, la protéine ligand humaine Fas ou une protéine ligand humaine Fas tronquée ou une variante de celle-ci, fonctionnellement équivalente, retenant les propriétés de hFasL, lesquelles consistent à fixer le récepteur de Fas et à induire l'apoptose, et liée soit directement soit indirectement à sa partie C-terminale, et d'autre part, un glycophospholipide. Cette protéine est utile pour prévenir ou traiter le rejet de greffe d'organe ou de tissu.
CA002232876A 1995-11-16 1996-11-15 Proteine de fusion du ligand fas Abandoned CA2232876A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523469.6A GB9523469D0 (en) 1995-11-16 1995-11-16 Organic compounds
GB9523469.6 1995-11-16

Publications (1)

Publication Number Publication Date
CA2232876A1 true CA2232876A1 (fr) 1997-05-22

Family

ID=10784000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232876A Abandoned CA2232876A1 (fr) 1995-11-16 1996-11-15 Proteine de fusion du ligand fas

Country Status (10)

Country Link
EP (1) EP0879285A1 (fr)
JP (1) JP2000500336A (fr)
CN (1) CN1202200A (fr)
AU (1) AU7684896A (fr)
BR (1) BR9611734A (fr)
CA (1) CA2232876A1 (fr)
CO (1) CO4520295A1 (fr)
GB (1) GB9523469D0 (fr)
WO (1) WO1997018307A1 (fr)
ZA (1) ZA969623B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6451759B1 (en) * 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
WO2000047740A2 (fr) * 1999-02-12 2000-08-17 Amgen Inc. Proteines associees au facteur de necrose des tumeurs
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
AU2926401A (en) * 2000-01-03 2001-07-16 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
AU784614B2 (en) * 2000-01-24 2006-05-11 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis
CA2413237C (fr) 2000-06-30 2013-09-10 University Of Louisville Research Foundation, Inc. Alteration des membranes cellulaires en vue d'obtenir de nouvelles fonctions
CA2812057A1 (fr) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions et procedes de traitement de malignites hematologiques
AU2018221171B2 (en) * 2017-02-17 2024-01-18 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
US11602547B2 (en) * 2017-03-10 2023-03-14 University Of Louisville Research Foundation, Inc. FasL-engineered biomaterials with immunomodulatory function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6237145U (fr) * 1985-08-23 1987-03-05
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH0590011A (ja) * 1991-09-26 1993-04-09 Anritsu Corp 感温抵抗体及びその製造方法
JPH05332845A (ja) * 1992-06-03 1993-12-17 Kobe Steel Ltd 温度検出器の出力変換方法および同装置
WO1995018819A1 (fr) * 1994-01-07 1995-07-13 Immunex Corporation Ligand fixant l'antigene fas

Also Published As

Publication number Publication date
JP2000500336A (ja) 2000-01-18
BR9611734A (pt) 1999-02-23
EP0879285A1 (fr) 1998-11-25
CO4520295A1 (es) 1997-10-15
CN1202200A (zh) 1998-12-16
GB9523469D0 (en) 1996-01-17
AU7684896A (en) 1997-06-05
ZA969623B (en) 1998-05-15
WO1997018307A1 (fr) 1997-05-22

Similar Documents

Publication Publication Date Title
US7659385B2 (en) Polynucleotides encoding molecules designated LDCAM
CA2162397C (fr) Ligands pour recepteurs flt3
Lasky et al. Cloning of a lymphocyte homing receptor reveals a lectin domain
US7939640B2 (en) Antibodies that bind B7L-1
US7041282B2 (en) Ligands for flt3 receptors
JP4402288B2 (ja) キメラのインターロイキン−６可溶性受容体／リガンドタンパク質、その類似体およびその使用
CA2232876A1 (fr) Proteine de fusion du ligand fas
CA2742517A1 (fr) Proteines hla-g et leurs utilisations pharmaceutiques
CA2200980C (fr) Recepteurs de lipoproteines de basse densite modifiees chez des mammiferes
EP1736482A1 (fr) Ligand recombinant trimeric de 4-1BB
CA2516834C (fr) Polypeptides et methodes d'obtention
EP1363942A2 (fr) Polypeptides d'un recepteur de lymphocytes t alpha/beta des murides specifique de la proteine hdm2, acides nucleiques les codant et leur utilisation
US6670135B1 (en) Semaphorin polypeptides
US6130068A (en) Viral encoded semaphorin protein receptor DNA and polypeptides
US20130084603A1 (en) B7l-1 polynucleotides
WO1994010188A1 (fr) Antigene d'activation cd69
MXPA94003806A (en) Ligands for receivers f

Legal Events

Date Code Title Description
FZDE Dead